Opus Genetics, Inc.IRDEarnings & Financial Report
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
Revenue
$1.1M
Gross Profit
N/A
Operating Profit
$-8.3M
Net Profit
$-7.8M
Gross Margin
N/A
Operating Margin
-748.9%
Net Margin
-698.3%
YoY Growth
-69.7%
EPS
$-0.30
Opus Genetics, Inc. Q2 FY2024 Financial Summary
Opus Genetics, Inc. reported revenue of $1.1M (down 69.7% YoY) for Q2 FY2024, with a net profit of $-7.8M (down 56.5% YoY) (-698.3% margin).
Key Financial Metrics
| Total Revenue | $1.1M |
|---|---|
| Net Profit | $-7.8M |
| Gross Margin | N/A |
| Operating Margin | -748.9% |
| Report Period | Q2 FY2024 |
Opus Genetics, Inc. Annual Revenue by Year
Opus Genetics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $14.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $14.2M |
| 2024 | $11.0M |
Opus Genetics, Inc. Quarterly Revenue & Net Profit History
Opus Genetics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $3.9M | -10.2% | N/A | N/A |
| Q3 FY2025 | $3.1M | -20.4% | $-17.5M | -566.9% |
| Q2 FY2025 | $2.9M | +159.2% | $-7.4M | -257.5% |
| Q1 FY2025 | $4.4M | +155.4% | $-8.2M | -187.5% |
| Q4 FY2024 | $4.3M | +154.4% | N/A | N/A |
| Q3 FY2024 | $3.9M | -67.6% | $-7.5M | -194.6% |
| Q2 FY2024 | $1.1M | -69.7% | $-7.8M | -698.3% |
| Q1 FY2024 | $1.7M | -2.2% | $-7.1M | -415.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.1M | $3.9M | $4.3M | $4.4M | $2.9M | $3.1M | $3.9M |
| YoY Growth | -2.2% | -69.7% | -67.6% | 154.4% | 155.4% | 159.2% | -20.4% | -10.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $51.8M | $44.8M | $40.4M | $36.9M | $48.2M | $38.7M | $36.1M | $50.2M |
| Liabilities | $5.8M | $4.2M | $6.1M | $11.3M | $24.3M | $21.2M | $30.2M | $34.9M |
| Equity | $46.1M | $40.6M | $34.3M | $6.7M | $5.1M | $17.5M | $6.0M | $15.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.7M | $-7.3M | $-5.1M | $-25.6M | $-9.0M | $-10.3M | $-6.2M | $-35.3M |